Molecular and cellular mechanisms of prevention of bone loss by beta blockers
β受体阻滞剂预防骨质流失的分子和细胞机制
基本信息
- 批准号:10594230
- 负责人:
- 金额:$ 44.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-21 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:ADRB1 geneAcuteAddressAdrenergic ReceptorAdrenergic beta-AntagonistsAtenololBindingBone DensityBone ResorptionCRISPR/Cas technologyCellsClinicalClinical TrialsCompetitive BindingDataDevelopmentFundingFutureGenesGeneticGenotypeGoalsGrantHDAC4 geneHealthHeterogeneityHormone replacement therapyHormonesHumanIndividualLinkMeasuresMediatingMicroRNAsModelingModificationMolecularMusNeckNorepinephrineObservational StudyOsteoblastsOsteoclastsOsteogenesisOsteoporosis preventionOutcomeParticipantPathway interactionsPeripheral Blood Mononuclear CellPharmacogeneticsPostmenopausal OsteoporosisPostmenopausePreventionPrevention strategyRandomized Controlled TrialsRiskSafetySamplingSignal PathwaySignal TransductionSourceSumTestingVariantViralWomanWomen&aposs Healthbeta-2 Adrenergic Receptorsbonebone healthbone losscirculating microRNAdrug discoveryefficacy evaluationfracture riskgenetic variantgenome-wideimprovedin vivoknock-downmRNA Expressionnovelnovel therapeuticsoverexpressionpersonalized medicinetreatment effecttreatment grouptreatment responsetreatment strategy
项目摘要
Abstract/Summary
Post-menopausal bone loss has been an unresolved clinical problem since the Women’s Health Initiative
showed the risks of hormone replacement therapy. To address this issue, a clinical trial using beta blockers
(BBs) to improve bone health has recently been funded entitled, “Beta1-selective blockade for prevention of
postmenopausal bone loss: A randomized controlled trial” (R01 AG065154-A1). While this trial will evaluate the
efficacy and safety of BBs for this indication, questions will remain about the mechanism and optimal use of
this prevention strategy. Heterogeneity of BB effects on bone outcomes have been observed and may be due
to pharmacogenetics, as we have discovered and validated pharmacogenetic variants in ADRB1 and HDAC4.
Furthermore, the mechanisms of treatment effect remain controversial. Although previous mouse studies
showed that the beneficial bone effects of BBs were due to competitive binding to B2-adrenergic receptors
(B2-ARs) on osteoblasts, many human studies have found B1-selective blockers to be associated with better
bone outcomes. In addition, we have discovered that miR-19a-3p, which we hypothesize to target B1-AR
(ADRB1), is associated with BB use and higher bone mineral density (BMD). We also show a
pharmacogenetic association in an ADRB1 variant, which is positively associated with miR-19a-3p expression.
In mouse studies, we have shown a novel direct effect of BB treatment on osteoclasts that is not mediated by
osteoblast signaling. In summary, our preliminary pharmacogenetic and microRNA results underscore the
importance of B1-AR in addition to B2-AR signaling for BB bone effects, and our mouse studies show evidence
of direct effects of BB treatment on osteoclasts in addition to indirect effects via osteoblasts. Our central
hypothesis is that genetic and microRNA (miRNA) variables associated with treatment response contribute to
modulation of B1-AR and B2-AR signaling pathways in osteoblasts and osteoclasts. We will test this
hypothesis via the following specific aims: 1) Measure the effect of in vivo atenolol treatment on differentiation
in participant-derived osteoclasts, discover and validate pharmacogenetic variants of atenolol treatment
response, and characterize their functional effects on osteoblasts and osteoclasts. 2) Use miRNA-seq to
identify circulating miRNAs associated with treatment response, and discover targets and validate mechanisms
in osteoblasts and osteoclasts. We propose to rigorously perform these aims using participant-derived samples
from the previously mentioned trial. This proposal will allow us to characterize the mechanisms of BB treatment
effect on bone in post-menopausal women and to create personalized treatment models.
摘要/摘要
自妇女健康倡议以来,绝经后骨质流失一直是一个悬而未决的临床问题
显示了激素替代疗法的风险。为了解决这个问题,一项使用β受体阻滞剂的临床试验
(BBS)最近获得了名为“Beta1--选择性阻断预防骨质疏松症”的资助。
绝经后骨丢失:一项随机对照试验“(R01 AG065154-A1)。虽然这场审判将评估
BBS的有效性和安全性对于这一适应症,关于其机制和最佳使用仍存在疑问
这一预防策略。已经观察到BB对骨结果的异质性影响,这可能是由于
对于药物遗传学,我们已经发现并验证了ADRB1和HDAC4中的药物遗传变体。
此外,治疗效果的机制仍存在争议。尽管之前对小鼠的研究
研究表明,BBS的有益骨骼作用是由于与B2-肾上腺素能受体的竞争结合
(B2-Ars)在成骨细胞上,许多人类研究发现B1选择性阻滞剂与更好的
骨骼的结果。此外,我们还发现miR-19a-3p,我们假设它以B1-AR为靶点
(ADRB1)与BB的使用和较高的骨矿密度(BMD)有关。我们还展示了一个
ADRB1变异中的药物遗传关联,这与miR-19a-3p的表达呈正相关。
在小鼠研究中,我们显示了BB治疗对破骨细胞的一种新的直接作用,这种作用不是由
成骨细胞信号。总而言之,我们的初步药物遗传学和microRNA结果强调了
除了B2-AR信号外,B1-AR在BB骨骼效应中的重要性,我们的小鼠研究表明
除通过成骨细胞的间接影响外,BB治疗对破骨细胞的直接影响。我们的中央
假设与治疗反应相关的遗传和微RNA(MiRNA)变量有助于
成骨细胞和破骨细胞中B1-AR和B2-AR信号通路的调控。我们将对此进行测试
假设通过以下特定目的:1)测量体内阿替洛尔治疗对分化的影响
在参与者来源的破骨细胞中,发现和验证阿替洛尔治疗的药物遗传学变体
反应,并表征其对成骨细胞和破骨细胞的功能影响。2)使用miRNA-seq
确定与治疗反应相关的循环miRNAs,并发现靶点和验证机制
在成骨细胞和破骨细胞中。我们建议使用参与者派生的样本严格执行这些目标
从前面提到的审判中。这项建议将使我们能够描述BB治疗的机制
对绝经后妇女骨骼的影响,并创造个性化的治疗模式。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHRISTINE Woods Lary其他文献
CHRISTINE Woods Lary的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHRISTINE Woods Lary', 18)}}的其他基金
Molecular and cellular mechanisms of prevention of bone loss by beta blockers
β受体阻滞剂预防骨质流失的分子和细胞机制
- 批准号:
10767459 - 财政年份:2022
- 资助金额:
$ 44.38万 - 项目类别:
Project 3: Beta blockers and their impact on fracture risk in nursing home residents taking atypical antipsychotics
项目 3:β 受体阻滞剂及其对服用非典型抗精神病药物的疗养院居民骨折风险的影响
- 批准号:
10246811 - 财政年份:2017
- 资助金额:
$ 44.38万 - 项目类别:
Project 3: Beta blockers and their impact on fracture risk in nursing home residents taking atypical antipsychotics
项目 3:β 受体阻滞剂及其对服用非典型抗精神病药物的疗养院居民骨折风险的影响
- 批准号:
9210675 - 财政年份:2017
- 资助金额:
$ 44.38万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 44.38万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 44.38万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 44.38万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 44.38万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 44.38万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 44.38万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 44.38万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 44.38万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 44.38万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 44.38万 - 项目类别:
Operating Grants